HTG Molecular Diagnostics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3305
- Today's High:
- $0.43
- Open Price:
- $0.34
- 52W Low:
- $0.2
- 52W High:
- $13.8044
- Prev. Close:
- $0.45
- Volume:
- 5460
Company Statistics
- Market Cap.:
- $1.06 million
- Book Value:
- 0.214
- Revenue TTM:
- $6.21 million
- Operating Margin TTM:
- -315.21%
- Gross Profit TTM:
- $-2009447
- Profit Margin:
- 0%
- Return on Assets TTM:
- -62.26%
- Return on Equity TTM:
- -343.21%
Company Profile
HTG Molecular Diagnostics Inc had its IPO on 2015-05-06 under the ticker symbol HTGM.
The company operates in the Healthcare sector and Healthcare Equipment & Supplies industry. HTG Molecular Diagnostics Inc has a staff strength of 53 employees.
Stock update
Shares of HTG Molecular Diagnostics Inc opened at $0.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.33 - $0.43, and closed at $0.35.
This is a -23.33% slip from the previous day's closing price.
A total volume of 5,460 shares were traded at the close of the day’s session.
In the last one week, shares of HTG Molecular Diagnostics Inc have slipped by -6.81%.
HTG Molecular Diagnostics Inc's Key Ratios
HTG Molecular Diagnostics Inc has a market cap of $1.06 million, indicating a price to book ratio of 6.2649 and a price to sales ratio of 1.0551.
In the last 12-months HTG Molecular Diagnostics Inc’s revenue was $6.21 million with a gross profit of $-2009447 and an EBITDA of $-19100410. The EBITDA ratio measures HTG Molecular Diagnostics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, HTG Molecular Diagnostics Inc’s operating margin was -315.21% while its return on assets stood at -62.26% with a return of equity of -343.21%.
In Q1, HTG Molecular Diagnostics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 12.8%.
HTG Molecular Diagnostics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-17.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into HTG Molecular Diagnostics Inc’s profitability.
HTG Molecular Diagnostics Inc stock is trading at a EV to sales ratio of 1.0425 and a EV to EBITDA ratio of -0.3462. Its price to sales ratio in the trailing 12-months stood at 1.0551.
HTG Molecular Diagnostics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.87 million
- Total Liabilities
- $6.56 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $6238
- Dividend Payout Ratio
- 0%
HTG Molecular Diagnostics Inc ended 2024 with $10.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.87 million while shareholder equity stood at $474502.00.
HTG Molecular Diagnostics Inc ended 2024 with $0 in deferred long-term liabilities, $6.56 million in other current liabilities, 2214.00 in common stock, $-234982279.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.00 million and cash and short-term investments were $6.56 million. The company’s total short-term debt was $3,557,473 while long-term debt stood at $0.
HTG Molecular Diagnostics Inc’s total current assets stands at $9.19 million while long-term investments were $0 and short-term investments were $3.57 million. Its net receivables were $1.13 million compared to accounts payable of $1.10 million and inventory worth $654917.00.
In 2024, HTG Molecular Diagnostics Inc's operating cash flow was $0 while its capital expenditure stood at $6238.
Comparatively, HTG Molecular Diagnostics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.35
- 52-Week High
- $13.8044
- 52-Week Low
- $0.2
- Analyst Target Price
- $6
HTG Molecular Diagnostics Inc stock is currently trading at $0.35 per share. It touched a 52-week high of $13.8044 and a 52-week low of $13.8044. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.48 and 200-day moving average was $3.14 The short ratio stood at 0.03 indicating a short percent outstanding of 0%.
Around 654.2% of the company’s stock are held by insiders while 74.6% are held by institutions.
Frequently Asked Questions About HTG Molecular Diagnostics Inc
Similar Industry Stocks (Healthcare Equipment & Supplies)
Most Active
Top Gainers
Top Losers
About
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.